In a report released today, Matt Miksic from Credit Suisse maintained a Buy rating on Stryker (SYK), with a price target of $237.00. The company’s shares closed last Friday at $179.73.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of 10.9% and a 69.6% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
Stryker has an analyst consensus of Moderate Buy, with a price target consensus of $202.93, which is a 5.3% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $213.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $226.31 and a one-year low of $124.54. Currently, Stryker has an average volume of 2.42M.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SYK in relation to earlier this year. Most recently, in March 2020, Srikant Datar, a Director at SYK bought 1,000 shares for a total of $59,700.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.
